Cargando…

Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis has become one of the more well-known autoimmune diseases affecting the brain and it is characterized by a multitude of progressive neuropsychiatric symptoms. The following case describes the clinical course of an 18-year-old female with excited...

Descripción completa

Detalles Bibliográficos
Autores principales: Neerukonda, Namita, Bliss, Michael, Jafroodifar, Abtin, Leontieva, Luba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305573/
https://www.ncbi.nlm.nih.gov/pubmed/32577332
http://dx.doi.org/10.7759/cureus.8689
_version_ 1783548490915250176
author Neerukonda, Namita
Bliss, Michael
Jafroodifar, Abtin
Leontieva, Luba
author_facet Neerukonda, Namita
Bliss, Michael
Jafroodifar, Abtin
Leontieva, Luba
author_sort Neerukonda, Namita
collection PubMed
description Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis has become one of the more well-known autoimmune diseases affecting the brain and it is characterized by a multitude of progressive neuropsychiatric symptoms. The following case describes the clinical course of an 18-year-old female with excited type catatonia secondary to anti-NMDA receptor encephalitis. The patient had been brought to the ED by her parents in an acutely psychotic state characterized by profound disorganization and vivid visual hallucinations. She was admitted to psychiatry and her hospital course was significant for both retarded and excited type catatonia, autonomic instability, and sensitivity to multiple neuroleptics. Given the atypicality of her symptoms and a family history of autoimmune disease, workup for autoimmune encephalitis was performed. MRI of the pelvis showed an indeterminate ovarian mass and laboratory studies were generally unremarkable. The catatonic symptoms resolved over the course of three weeks, eventually responding to a combination of lorazepam and olanzapine. Following discharge, a cerebrospinal fluid (CSF) panel resulted with positive titers for anti-NMDA receptor antibodies. This case illustrates the need to consider autoimmune encephalitis in cases of catatonia. It also presents a case in which symptoms of anti-NMDA receptor encephalitis potentially remitted without immunotherapy or mass resection.
format Online
Article
Text
id pubmed-7305573
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-73055732020-06-22 Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis Neerukonda, Namita Bliss, Michael Jafroodifar, Abtin Leontieva, Luba Cureus Neurology Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis has become one of the more well-known autoimmune diseases affecting the brain and it is characterized by a multitude of progressive neuropsychiatric symptoms. The following case describes the clinical course of an 18-year-old female with excited type catatonia secondary to anti-NMDA receptor encephalitis. The patient had been brought to the ED by her parents in an acutely psychotic state characterized by profound disorganization and vivid visual hallucinations. She was admitted to psychiatry and her hospital course was significant for both retarded and excited type catatonia, autonomic instability, and sensitivity to multiple neuroleptics. Given the atypicality of her symptoms and a family history of autoimmune disease, workup for autoimmune encephalitis was performed. MRI of the pelvis showed an indeterminate ovarian mass and laboratory studies were generally unremarkable. The catatonic symptoms resolved over the course of three weeks, eventually responding to a combination of lorazepam and olanzapine. Following discharge, a cerebrospinal fluid (CSF) panel resulted with positive titers for anti-NMDA receptor antibodies. This case illustrates the need to consider autoimmune encephalitis in cases of catatonia. It also presents a case in which symptoms of anti-NMDA receptor encephalitis potentially remitted without immunotherapy or mass resection. Cureus 2020-06-18 /pmc/articles/PMC7305573/ /pubmed/32577332 http://dx.doi.org/10.7759/cureus.8689 Text en Copyright © 2020, Neerukonda et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Neerukonda, Namita
Bliss, Michael
Jafroodifar, Abtin
Leontieva, Luba
Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title_full Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title_fullStr Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title_full_unstemmed Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title_short Olanzapine and Lorazepam Used in the Symptomatic Management of Excited Catatonia Secondary to Anti-N-Methyl-D-Aspartate Receptor Encephalitis
title_sort olanzapine and lorazepam used in the symptomatic management of excited catatonia secondary to anti-n-methyl-d-aspartate receptor encephalitis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305573/
https://www.ncbi.nlm.nih.gov/pubmed/32577332
http://dx.doi.org/10.7759/cureus.8689
work_keys_str_mv AT neerukondanamita olanzapineandlorazepamusedinthesymptomaticmanagementofexcitedcatatoniasecondarytoantinmethyldaspartatereceptorencephalitis
AT blissmichael olanzapineandlorazepamusedinthesymptomaticmanagementofexcitedcatatoniasecondarytoantinmethyldaspartatereceptorencephalitis
AT jafroodifarabtin olanzapineandlorazepamusedinthesymptomaticmanagementofexcitedcatatoniasecondarytoantinmethyldaspartatereceptorencephalitis
AT leontievaluba olanzapineandlorazepamusedinthesymptomaticmanagementofexcitedcatatoniasecondarytoantinmethyldaspartatereceptorencephalitis